FRESENIUS SE & CO. KGAA #FutureFresenius: Simplification and focus drives sustained performance
Delivering continued momentum in Q3/24; upgrading FY/24 outlook
Berenberg European Conference - London
04 December 2024
#FutureFresenius | Attachments |
Financial review Q3/24 02
#FutureFresenius 03
Attachments 04
Q3/24
Continued momentum and sustained performance
Further deleveraging based on excellent cash flow; leverage target ratio under review
Strong top-line: 9% organic revenue growth
Ongoing momentum at Biopharma: Delivering positive EBIT in Q3/24
Structural productivity target for FY/24 already achieved YTD
Strong bottom-line traction: High single-digit EBIT and EPS growth in Q3/24
Outlook upgraded
Before special items; at constant currency
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations
#Future
Fresenius
4
Financial review Q3/24 | ||||||||
#FutureFresenius
Attachments
Q3/24
Kabi and Helios above structural growth band
Fresenius Kabi | Fresenius Helios |
Revenue
(Org. € 2.1bn Growth)
4-7%
+11%1
4-6% | |
€ 3.1bn | +8% |
EBIT € 335m (Margin)
14-17%
15.9%
10-12%
€ 244m | 7.9% | ||
Key Messages
- Growth Vectors posting 16% organic revenue growth; yet again in structural margin band with EBIT margin of 14.5%
- EBITDA margin of 21.8% in Q3/24
- EBIT margin improved by 160 bps YoY driven by Growth Vectors and EBIT-positiveBiopharma
- Strong organic revenue growth above top-end of structural growth band
- EBIT margin solid despite usual seasonality
- Strong YoY EBIT growth of 6% cc
Before special items
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations | 5 |
Financial review Q3/24 | #FutureFresenius | |
Kabi: Growth Vector momentum continues
Attachments
Biopharma
Q3/24 Revenue
€177m
+66%
yoy1
- FDA and EMA approval for
Ustekinumab biosimilar - mAbxience and Teva announced second strategic global license agreement
- Evio announced direct purchase agreement with Kabi for Adalimumab
MedTech
Q3/24 Revenue
€384m
+7%
yoy1
- Contract with SSM Health for Ivenix Infusion System with over 6,500 pumps
- Development agreement with Cellular Origins for scalable automation of manufacturing of cell and gene therapies
Nutrition
Q3/24 Revenue
€597m
+11%
yoy1
- Launch of Peditrace Novum in Europe, our pediatric trace element solution
- China: First sales of products under "Enteral Food" regulation produced in local Wuxi plant
Pharma
Q3/24 Revenue
€957m
+6%
yoy1
- Investment decided for new production line for infusion solutions and ready-to-use medication solutions in Kutno, Poland
- Launches: Lacosamide (EU) and Cetrorelix Ace- tate for Injection Kit (US)
- Divestment of IV manufacturing site in Chile
1 Organic growth; adjusted for accounting effects related to Argentina hyperinflation
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations
6
Biopharma: Strong focus on market penetration reflected in recent successes
May 27, 2024
Fresenius Announces
FDA Acceptance for
Review of Denosumab
Biosimilar Application
April 4, 2024 | |
mAbxience and Teva | July 11, 2024 |
Announce Strategic Global | Fresenius Announces |
License Agreement for | EMA Acceptance for |
Biosimilar Oncology | Review of Denosumab |
Treatment | Biosimilar Candidates |
October 3, 2024
mAbxience and Teva Announce
Second Strategic Global License
Agreement for Biosimilar
Oncology Treatment Candidate
October 1, 2024
Evio Announces Groundbreaking
Direct Purchase Agreement for
Adalimumab Biosimilar
September 30, 2024
U.S. FDA Approval for
OtulfiTM, an Ustekinumab
Biosimilar
September 27, 2024
European Commission
Approval for FYB202, an
Ustekinumab Biosimilar
Q2 2024 | Q3 2024 | Q4 2024 | ||
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations | 7 |
Tyenne: Strong momentum building
RoE | • | Launched in 17 EU countries, UK & KSA |
19% market share in EU5 (as of Aug'24) | ||
RoW • | ||
• | Essentially all GER sick funds contracted | |
• | 95% tender win rate in FRA |
Tyenne market shares | ESP 26% |
GER 24% |
UK 19%
EU5 19%
FRA 13%
ITA 3%
Nov Dec Jan Feb Mar Apr May Jun Jul Aug 2024
Source: IQVIA Monthly Data
US Milestones | |||||||||||||||||||||||
FDA approval | |||||||||||||||||||||||
IV & SC | Billing code | ||||||||||||||||||||||
Launch | activation | ||||||||||||||||||||||
Launch | |||||||||||||||||||||||
IV | SC | ||||||||||||||||||||||
Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | ||||||||||||||||
2024 |
- Shipping under >35 payor client agreements
- Permanent, product-specific Q-Code and pass-through payment status granted
- Contracted several large PBMs/IDNs; continuously adding new contracts
- Largely moving from parity to exclusive IL6/Tocilizumab coverage in '25
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations | 8 |
Helios delivering consistent strong organic growth
Helios Germany
Q3/24 Revenue
€1,940m
+8%
yoy1
- Key parameter for 2025 DRG inflator set at 4.41%
- Antibody-drugconjugates: New era of targeted breast cancer therapy
- Dedicated Helios performance programme underway to drive further operational excellence and act against ended energy relief funding
Helios Spain
Q3/24 Revenue
€1,142m
+8%
yoy1
- Start of construction of new hospital in Badajoz
- Quirónsalud patient portal exceeds 7 million users - incorporating one million new users in less than a year
-
La Luz University Hospital becoming one of only five hospitals in Spain accredited as an Academic Medical
Center
1 Organic growth
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations | 9 |
20% | Kabi: | Helios | Kabi: | |||||
Growth | Pharma | |||||||
Vectors | 16% | |||||||
Growth | ||||||||
Revenue | 15% | |||||||
Vectors | ||||||||
10% | ||||||||
Organic | 9% Fresenius | driving | ||||||
Group | organic | |||||||
growth | 8% | |||||||
growth | ||||||||
yoy | 5% | 6% | ||||||
momentum | ||||||||
0% | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | ||
Q1/23 |
Growth rates adjusted for Argentina hyperinflation
Berenberg European Conference, 04 December 2024 © Fresenius SE & Co. KGaA Investor Relations | 10 |
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on December 04, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on December 03, 2024 at 00:07:09.348.
